Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ASCO's Richard Schilsky On State-of-the-Art Oncology Trials

Executive Summary

ASCO's chief medical officer Richard Schilsky discusses innovative clinical trial designs in oncology, challenges facing developers of cancer combination therapies and future developments for the society's value frameworks.

You may also be interested in...

Oncology Drug Value Tools From NCCN, ASCO To Get Real-World Testing

Officials from oncology professional organizations discuss next steps in the development of their frameworks for valuing oncology drugs.

Genomics-Driven Trials Built To Be Fast And Flexible

Pioneering enrollment strategies are coupled with adaptive statistical designs in the next wave of basket trials from NCI, ASCO and Novartis.

Cancer Trials & Tribulations: Combinations Are Easier Said Than Done

Combinations of checkpoint inhibitors and targeted drugs are said to hold the key to better, more durable results in the future. But recent studies highlighted some big challenges, like unexpected toxicities, prompting a call for more preclinical research to better predict winning combinations.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts